More aggressive rhuFab V2 dosing scheme well-tolerated

May 5, 2003

Ft. Lauderdale-With use of a dose-escalating administration strategy,the anti-VEGF antibody fragment rhuFab V2 is safe and well-tolerated ineyes with neovascular AMD at doses as high as 2 mg and at a treatment frequencyas often as every 2 weeks, according to the results of a Phase I, multicenter,randomized trial presented by Philip J. Rosenfeld, MD.